Clinical Trial Update: A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery [Phase 1]

View source ↗

Summary

Phase 1 trial in colorectal cancer evaluating ezabenlimab or pembrolizumab in combination with BI 765063; the study was terminated and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• BI 765063
• Pembrolizumab (pembrolizumab)
• ezabenlimab (ezabenlimab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Colorectal Cancer | Phase 1 | Status: TERMINATED | Results posted: 2025-03-13